Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04489420
Other study ID # CYNK001-GBM-001
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date October 1, 2020
Est. completion date August 10, 2021

Study information

Verified date August 2022
Source Celularity Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date August 10, 2021
Est. primary completion date August 10, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically confirmed glioblastoma multiforme (GBM) and are at first or second relapse. 2. = 18 years of age 3. Have measurable disease of at least one solitary lesion with a dimension between 1 cm and 5 cm according to RANO 4. Karnofsky performance status (KPS) = 60 5. Adequate organ function defined by laboratory values as follows: Creatinine < 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance =40 mL/min, Bilirubin < 20% above the upper limit of normal, AST and ALT = 2.5 the upper limit of normal. 6. Absolute Neutrophil count baseline (ANC) =1500 cells/uL, Hemoglobin baseline = 9.0 g/dL and Platelets baseline = 100,000 cells/uL prior to the start of study treatment. 7. Female of childbearing potential (FCBP) must not be pregnant and agree to not becoming pregnant for at least 42 days following the start of the treatment. 8. Patients with HIV/AIDs are eligible if they have not had an opportunistic infection within the past 12 months 9. Patients with chronic HBV infection or patients with current or a history of HCV infection are allowed if: 1. have an HBV viral load below the limit of quantification and be on viral suppressive therapy 2. have current HCV infection, they should be on concurrent HCV treatment and the HCV viral load must be below the limit of quantification 3. have a history of HCV infection should have completed curative antiviral treatment and require HCV viral load below the limit of quantification Exclusion Criteria: 1. Had prior radiation therapy within 12 weeks of screening MRI unless there is unequivocal histological confirmation of tumor progression 2. Subjects on growth factors therapy with less than 4 weeks washout period (for short-acting growth factors, such as G-CSF, GM-CSF 5-day wash-out for longer-acting factors (such as Neulasta) 10 days 3. Radiotherapy, chemotherapy, or other investigational agents within 4 weeks 4. Prior cellular or gene therapy at any time 5. Clinical or laboratory signs for immunodeficiency or under immunosuppressive medication or steroids greater than15 mg prednisone or equivalent per day 6. History of malignancy, other than GBM, unless the subject has been free of disease for > 3 years from the date of signing the ICF. Exceptions include the following noninvasive malignancies: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, Incidental histological finding of prostate cancer (TNM stage of T1a or T1b) 7. Active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy

Study Design


Intervention

Biological:
CYNK001-IV
Planned Starting dose dor IV 1.2x10^9 cells/dose
CYNK001-IT
Planned starting dose for IT 200 x10^6 +/- 50 x10^6 cells dose

Locations

Country Name City State
United States The Univeristy of Texas MD ANderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
Celularity Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants who experienced a Dose-Limiting Toxicity (DLT) Defined as the maximum dose safely administered intravenously or Intratumoral for the treatment of patients with GBM. Day 42
Primary Adverse Events (AEs) Defined as the number and Severity of Adverse Events 1 year
Secondary Overall Response Rate Defined as the proportion of subjects with best overall response of either complete response (CR) or partial response (PR) 1 year
Secondary Duration of Response Rate Defined as duration from first observation of partial response (PR) or better to the date of disease progression per RANO criteria 1year
Secondary Progression-free survival Defined as date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria or death (regardless of cause of death), whichever comes first 1year
Secondary Time to porgression Defined as the date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria, with deaths from causes other than progression censored 1year
Secondary Overall Survival Defined as the date of the first CYNK-001 infusion to the date of death 1year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05023551 - Study of DSP-0390 in Patients With Recurrent High-Grade Glioma Early Phase 1
Recruiting NCT06059690 - Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells Phase 1/Phase 2
Recruiting NCT04116411 - A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients Phase 2
Terminated NCT01902771 - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Completed NCT00038493 - Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Recruiting NCT01923922 - CT Perfusion in the Prognostication of Cerebral High Grade Glioma N/A
Completed NCT01956734 - Virus DNX2401 and Temozolomide in Recurrent Glioblastoma Phase 1
Completed NCT01402063 - PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Phase 2
Completed NCT01301430 - Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. Phase 1/Phase 2
Suspended NCT01386710 - Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma Phase 1/Phase 2
Active, not recruiting NCT00995007 - A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Phase 2
Terminated NCT00990496 - A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) Phase 1
Terminated NCT01044966 - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma Phase 1/Phase 2
Completed NCT00402116 - Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Phase 1/Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Completed NCT00504660 - 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Phase 2
Recruiting NCT05366179 - Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc Phase 1